Phase 1/2 Open‑Label Study Of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 or L858R ± T790M) Non‑Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Mavelertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
- 14 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2018 Planned End Date changed from 1 Jul 2022 to 12 Jul 2022.
- 13 Mar 2018 Planned primary completion date changed from 1 Mar 2021 to 28 Mar 2021.